GlassScriptPhysician profile
Radha Rao
NPI 1699746016
$1,805.93
in general payments reported to CMS, 2019-2025
37 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $34.81 · 2021: $318 · 2022: $116 · 2023: $150 · 2024: $385 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $669 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $669.33 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $200.59 | 2019-2024 | Rybrevant, Tecvayli, Darzalex |
| Seagen INC. | $172.56 | 2019-2021 | |
| Abbvie INC. | $157.05 | 2021-2025 | |
| Genentech USA, INC. | $119.94 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $117.43 | 2019-2024 | Enhertu, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $105.25 | 2019-2025 | Opdualag, Opdivo |
| Pharmaessentia USA Corporation | $100.61 | 2023-2025 | Besremi |
| Merck Sharp & Dohme LLC | $96.98 | 2019-2025 | Keytruda |
| Amgen INC. | $54.08 | 2019-2022 | |
| Daiichi Sankyo INC. | $49.41 | 2024-2025 | Enhertu |
| Tesaro, INC. | $45.12 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $40.00 | 2019 | |
| Incyte Corporation | $39.95 | 2019-2024 | Monjuvi, Jakafi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $37.44 | 2024 | |
| Stemline Therapeutics INC. | $34.39 | 2023 | Orserdu |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $33.72 | 2024-2025 | Ninlaro, Alunbrig |
| Servier Pharmaceuticals LLC | $32.24 | 2021-2024 | |
| Celgene Corporation | $31.72 | 2019-2021 | |
| Genzyme Corporation | $29.71 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $29.71 | 2022-2024 | Xpovio |
| Glaxosmithkline, LLC. | $27.89 | 2020-2021 | |
| Lilly USA, LLC | $25.44 | 2019-2024 | Jaypirca, Verzenio |
| Gilead Sciences, INC. | $24.27 | 2021-2022 | |
| Emd Serono, INC. | $23.51 | 2019 | |
| Sun Pharmaceutical Industries INC. | $23.49 | 2019 | |
| Genmab U.S., INC. | $18.92 | 2024 | Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.20 | 2023 | Gilotrif |
| Aveo Pharmaceuticals, INC. | $15.10 | 2021 | |
| Tg Therapeutics, INC. | $13.49 | 2021 | |
| Dendreon Pharmaceuticals LLC | $12.47 | 2019 | |
| Taiho Oncology, INC. | $12.34 | 2022 | |
| Astellas Pharma US INC | $12.22 | 2022 | |
| Agios Pharmaceuticals, INC. | $11.71 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.68 | 2019 | |
| Pfizer INC. | $11.18 | 2019 | |
| Clovis Oncology, INC. | $9.63 | 2019 | |
| Heron Therapeutics, INC. | $9.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radha Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.